Mark Day

Biography

Dr. Day is currently an Associate Professor of Neuroscience at Yale University. Most recently he served as Head, CNS Virtual Discovery at Purdue Pharma. Prior to joining Purdue, Dr. Day served as Executive Director, Head of External Research & Scouting at Alexion Pharmaceuticals, Inc. In this role he established the team, developed the business strategy and worked to get the endorsement of a venture fund. Prior to this, he led CNS Business Development at BMS and was the responsible for the identification, evaluation and facilitated the acquisition of iPierian for their humanized monoclonal Tau antibody for the treatment of Progressive Supra Nuclear Palsy, which has since been acquired by Biogen. Mark also served as the Head of Translational Imaging and Biochemical Biomarkers at Abbott Labs, and led Wyeth’s CNS translational medicine research. During this tenure Mark identified and implemented 17 research and development collaborations. His PhD was conducted at Cardiff University, and his Post Doctoral studies were under Professor RG Morris at The University of Edinburgh. He has published over 60 peer reviewed journal articles (e.g. Nature, Science, Nature Neuroscience, Neuroimaging etc.) and has been successful in identifying the best ways to optimize and mobilize internal and external resources to ensure the building of highly motivated and effective teams.

Research Interest

Neuroscience